Venglustat Gaucher Disease Type 3 Drug Profile
Venglustat
Gaucher Disease Type 3 Drug Profile
Venglustat is a small molecule drug targeting UGCG, developed by Sanofi. On March 18, 2026, it was granted Breakthrough Therapy designation in the United States for the treatment of Gaucher Disease, Type 3 — a rare neuronopathic lysosomal storage disorder with limited treatment options beyond enzyme replacement therapy.
Breakthrough Therapy designation for Gaucher Disease Type 3 — March 2026
Venglustat is a small molecule drug targeting UDP-glucose ceramide glucosyltransferase (UGCG), developed by Sanofi. On March 18, 2026, it was granted Breakthrough Therapy designation in the United States for the treatment of Gaucher Disease, Type 3. This designation reflects serious unmet need in a rare neuronopathic lysosomal storage disorder where existing enzyme replacement therapy (ERT) cannot adequately address the neurological component of the disease.
| Drug name | Venglustat |
| Target | UGCG (UDP-glucose ceramide glucosyltransferase) |
| Drug type | Small molecule drug |
| Developer | Sanofi |
| Indication | Gaucher Disease, Type 3 |
| Designation | Breakthrough Therapy designation (United States) |
| Designation date | March 18, 2026 |
| Patents | 178 |
| Clinical trials | 19 (Nervous System Diseases) |
19 clinical trials in Nervous System Diseases, 178 patents
According to the Synapse database, venglustat’s development program primarily focuses on the field of Nervous System Diseases. A total of 19 clinical trials have been conducted across its development history. The 178 patents associated with venglustat reflect the breadth of Sanofi’s IP position covering the substrate reduction therapy approach for lysosomal storage disorders.
UGCG inhibition as a substrate reduction strategy for Gaucher Disease Type 3
Gaucher disease type 3 (chronic neuronopathic Gaucher disease) is an autosomal recessive lysosomal storage disorder caused by mutations in the GBA1 gene, leading to deficient activity of the enzyme β-glucocerebrosidase and subsequent accumulation of glucosylceramide within macrophages (Gaucher cells). This results in multisystem involvement, including hepatosplenomegaly, anemia, thrombocytopenia, and bone disease, along with progressive but relatively slower-onset neurological manifestations such as oculomotor abnormalities (especially horizontal gaze palsy), ataxia, seizures, and cognitive impairment.
Epidemiologically, type 3 is less common than type 1 but more prevalent than the acute neuronopathic type 2, with higher frequencies reported in certain regions such as Northern Europe, the Middle East, and parts of Asia. Overall, Gaucher disease affects approximately 1 in 40,000 to 60,000 individuals globally, though incidence varies by population.
UGCG: the glucosylceramide synthesis gatekeeper
UDP-glucose ceramide glucosyltransferase (UGCG), also known as glucosylceramide synthase, is an integral membrane enzyme primarily localized to the cytosolic face of the Golgi apparatus, characterised by multiple transmembrane domains. Functionally, UGCG catalyzes the transfer of glucose from UDP-glucose to ceramide, generating glucosylceramide — the first glycosphingolipid in the biosynthetic pathway of complex glycosphingolipids.
UGCG · Enzyme inhibition · Substrate reductionCeramide/glycosphingolipid balance and downstream signalling
Through its role in glucosylceramide synthesis, UGCG regulates the balance between pro-apoptotic ceramide and pro-survival glycosphingolipids, thereby influencing cell proliferation, differentiation, and survival. UGCG is closely linked to sphingolipid metabolic pathways and modulates downstream signalling cascades such as PI3K/AKT, MAPK/ERK, and NF-κB, which are involved in inflammation, oncogenesis, and drug resistance.
PI3K/AKT · MAPK/ERK · NF-κBPhase 3 active-comparator study vs enzyme replacement therapy in GD3
The pivotal trial supporting venglustat’s Breakthrough Therapy designation is a Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (GD3) Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ERT).
The active-comparator design — comparing venglustat against ERT in patients who have already achieved therapeutic goals on ERT — is notable because it tests whether substrate reduction therapy can maintain systemic disease control while also addressing the neurological manifestations that ERT cannot reach. Enrollment of both adult and pediatric patients reflects the disease’s presentation across age groups.
| Phase | Phase 3 |
| Design | Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator |
| Population | Adult and pediatric patients with Gaucher Disease Type 3 (GD3) |
| Eligibility | Patients who have reached therapeutic goals with Enzyme Replacement Therapy (ERT) |
| Comparator | Enzyme Replacement Therapy (ERT) |
25 drugs targeting UGCG — substrate reduction therapy in focus
According to the Synapse Database, there are currently 25 drugs targeting UGCG. Venglustat operates in a competitive landscape for lysosomal storage disorder treatment, where substrate reduction therapy is an established but evolving approach.
ERT vs substrate reduction: the GD3 treatment divide
Enzyme replacement therapy is the established standard of care for systemic Gaucher disease manifestations but cannot cross the blood-brain barrier to address neurological involvement in Type 3. Venglustat, as a small molecule, is designed to reach the central nervous system — positioning substrate reduction therapy as the primary pharmacological approach for the neurological component.
Breakthrough Therapy: regulatory signal for unmet neurological need
The Breakthrough Therapy designation for Gaucher Disease Type 3 reflects the FDA’s recognition of serious unmet need in a disease subtype where neurological progression is poorly managed by available ERT. This designation signals an expedited development and review pathway, aligning venglustat with other rare disease programs receiving accelerated regulatory attention.
UGCG as an oncology target: the 25-drug landscape
UGCG’s role in modulating PI3K/AKT, MAPK/ERK, and NF-κB signalling cascades — pathways involved in inflammation, oncogenesis, and drug resistance — makes it a target of interest beyond lysosomal storage disorders. Among the 25 drugs targeting UGCG, programs span rare disease, oncology, and metabolic indications, reflecting the broad biology of glycosphingolipid synthesis.
Sanofi’s rare disease position: 178-patent IP moat
With 178 patents associated with venglustat, Sanofi has built a substantial IP position around UGCG inhibition for lysosomal storage disorders. The breadth of this portfolio — covering composition of matter, methods of treatment, and formulation — creates a significant competitive barrier for potential follow-on programs targeting the same mechanism in Gaucher disease.
Venglustat — key questions answered
Venglustat is a small molecule drug targeting UGCG developed by Sanofi. On March 18, 2026, it was granted Breakthrough Therapy designation in the United States for the treatment of Gaucher Disease, Type 3.
According to the Synapse database, venglustat has been studied in 19 clinical trials, primarily in the field of Nervous System Diseases.
According to the Synapse database, there are 178 patents associated with venglustat.
Gaucher disease type 3 (chronic neuronopathic Gaucher disease) is an autosomal recessive lysosomal storage disorder caused by mutations in the GBA1 gene, leading to deficient activity of the enzyme β-glucocerebrosidase and subsequent accumulation of glucosylceramide within macrophages (Gaucher cells). This results in multisystem involvement, including hepatosplenomegaly, anemia, thrombocytopenia, and bone disease, along with progressive neurological manifestations such as oculomotor abnormalities (especially horizontal gaze palsy), ataxia, seizures, and cognitive impairment.
UDP-glucose ceramide glucosyltransferase (UGCG), also known as glucosylceramide synthase, is an integral membrane enzyme primarily localized to the cytosolic face of the Golgi apparatus. Functionally, UGCG catalyzes the transfer of glucose from UDP-glucose to ceramide, generating glucosylceramide, the first glycosphingolipid in the biosynthetic pathway of complex glycosphingolipids. Through this role, UGCG regulates the balance between pro-apoptotic ceramide and pro-survival glycosphingolipids, thereby influencing cell proliferation, differentiation, and survival.
According to the Synapse Database, there are currently 25 drugs targeting UGCG.
Data on this page is sourced from the PatSnap Synapse database and is for reference only. Dataset represents a snapshot of available records as of March 2026.